Santhera Pharmaceuticals has entered into an exclusive license agreement with Chiesi Group Farmaceutici, under which Chiesi will in-license Raxone for the treatment of LHON for a total consideration of as much as €93 million, comprising an upfront payment of €44 million and near- to mid-term sales milestone payments of as much as €49 million.    Chiesi Group is in-licensing the rights to Raxone in LHON and all other ophthalmological indications worldwide except the U.S. and Canada, where Santh...